Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institute of Mental Health (NIMH) |
ClinicalTrials.gov Identifier: | NCT00237848 |
This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia Schizoaffective Disorder |
Drug: D-serine Behavioral: Cognitive retraining |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment |
Official Title: | D-Serine Augmentation of Cognitive Retraining in Schizophrenia |
Estimated Enrollment: | 72 |
Study Start Date: | February 2005 |
This study is based on the hypothesis that by increasing NMDA receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.
Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Richa Yadava, M.D. | 203-932-5711 ext 4249 | richa.yadava@yale.edu |
India, Karnataka | |
National Institute of Mental Health and Neurosciences | Recruiting |
Bangalore, Karnataka, India, 560029 | |
Contact: Chittaranjan Andrade, M.D. 91-80-6566814 andrade@nimhans.kar.nic.in |
Principal Investigator: | Deepak C D'Souza, M.D. | Yale University |
Study ID Numbers: | RPA/020/03, 103T-363 |
Study First Received: | September 13, 2005 |
Last Updated: | April 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00237848 |
Health Authority: | India: Ministry of Health; United States: Federal Government |
Schizophrenia Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |